Manufacturing

Agnes Shanley is senior editor of Pharmaceutical Technology.

Articles

From scale-up and tech transfer to analytical method development and quality testing, alliances between innovators and contract partners, and between CDMOs and technology vendors, are taking more therapies from lab to patient.



Collaboration Takes Cell and Gene Therapies Closer  to Their Full Potential

The 40,000-ft.2 facility will feature eight cleanrooms with configurations for the production of cell and viral vector products.

Fujifilm to Establish New Manufacturing and Innovation Center in Massachusetts 

The acquisition significantly expands Precision Medicine Group’s cell and gene therapy expertise.

Precision Medicine Group Acquires Project Farma

Under the terms of the agreement, operations will be initiated at Lonza’s Houston, TX Center of Excellence where Lonza will handle process development activities for late-clinical and commercial-scale GMP manufacturing of the cell therapy.

Lonza to Partner with Capricor Therapeutics for the Development of Duchenne Muscular Dystrophy Cell Therapy 

The collaboration includes the development, commercialization, and supply of Orgenesis’ pipeline in South Korea and Japan and the development and commercialization of Cure Therapeutics’ pipeline on a global basis.

Orgenesis and Cure Therapeutics Form Joint Venture for Cell and Gene Therapies

The companies have entered into an agreement for next-generation, mesothelin-directed CAR-T cell therapies for the treatment of solid tumors. 

Bayer and Atara Biotherapeutics Enter into Solid Tumor Treatment Agreement

The collaboration addresses the need for risk mitigation plans in cell therapies.

Cytiva and 4Tune Engineering Collaborate on Cell Therapy Quality Risk Management

Behzad Mahdavi, PhD, will join a team of experts in the company’s Science and Technology Group to fast-track the adoption of new development and drug delivery technologies and manufacturing processes and techniques.



Catalent Appoints New Vice President of Open Innovation, Biologics, Cell and Gene Therapy

Bone Therapeutics has reported the completion of Catalent’s acquisition of Skeletal Cell Therapy Support SA (SCTS)—Bone Therapeutics’ cell therapy manufacturing subsidiary.

Catalent Completes Acquisition of Bone Therapeutics’ Cell Therapy Manufacturing Subsidiary

Mogrify’s new technology platform, EpiMOGRIFY, can predict cellular switches important for determining cell identity, cell maintenance, directed differentiation, and cell conversion.

Manufacturing, Cell Therapies